> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Permanent Injunction Against 3 Illinois Companies
- URL: https://www.fdaweb.com/permanent-injunction-against-3-illinois-companies/
- Published: 2018-07-31T12:00:00.000Z
- Updated: 2026-09-15T00:22:57.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5142008

An Illinois federal court has entered a permanent injunction against three related Chicago companies — Global Marketing Enterprises, Lifeline Nutrients Corp., and Pronto Foods Company — and their owner **Eduardo Chua** and operations manager **Haidee Dawis**. The Justice Department [says](https://www.justice.gov/opa/pr/district-court-enters-permanent-injunction-against-chicago-companies-stop-distribution?ref=fdaweb.com) the injunction prevents the defendants from manufacturing, selling, and distributing adulterated and misbranded dietary supplements and unapproved and misbranded drugs.

A 7/26 Justice Department complaint says the defendants manufacture, package, label, and distribute numerous products in violation of the Federal Food, Drug, and Cosmetic Act (FFDCA). It also says their dietary supplements were adulterated because they were not manufactured, prepared, packed, labeled, or held in compliance with current good manufacturing practice regulations.

“FDA inspections of defendants’ plant in 2015 and 2017 revealed numerous failures to comply with CGMP regulations, including the failure to establish specifications for the identity, strength, composition, and purity of their products and the failure to establish and follow written sanitation procedures,” the Justice Department statement says. “The complaint also alleges that many of the labels on defendants’ supplements were deficient and caused the products to be misbranded under the FFDCA.”

The defendants also reportedly marketed numerous products as drugs by making claims that the products could help treat or prevent a host of serious diseases. The complaint alleges that the defendants’ disease-related treatment claims were unsupported by any well-controlled clinical studies or other credible scientific substantiation.

The defendants agreed to settle the litigation and be bound by the consent decree of permanent injunction, the department says. The decree requires that if the defendants wish to resume manufacturing and distributing dietary supplements in the future, they must implement the remedial measures set forth in the consent decree, notify FDA of the measure they have taken, and obtain written approval from FDA that they appear to be in compliance with both the terms of the consent decree and the provisions of the FFDCA.